Toll-like receptors 1-5 (TLR1-5)

Toll-like receptors 1 through 5 (TLR1-5) are integral components of the innate immune system, functioning as pattern recognition receptors (PRRs) that detect distinct pathogen-associated molecular patterns (PAMPs). These transmembrane proteins are located either on the cell surface (TLR1, TLR2, TLR4, and TLR5) or within endosomal compartments (TLR3). Each receptor specializes in identifying specific microbial signatures: TLR4 recognizes lipopolysaccharides from Gram-negative bacteria, TLR5 detects bacterial flagellin, and TLR3 identifies double-stranded RNA (NIH, StatPearls). Upon ligand binding, these receptors initiate signaling pathways, primarily via the MyD88 or TRIF adapter proteins, which culminate in the activation of transcription factors like NF-κB and the subsequent production of pro-inflammatory cytokines and interferons (UniProt). In a clinical context, TLR1-5 are high-value therapeutic targets for both immune stimulation and suppression. TLR agonists, such as Monophosphoryl lipid A (a TLR4 agonist), are widely utilized as vaccine adjuvants to enhance the potency and durability of immune responses. Conversely, antagonists are being developed to mitigate pathological inflammation in conditions like sepsis, rheumatoid arthritis, and systemic lupus erythematosus (PubMed, PMID: 30141315). The therapeutic challenge lies in achieving localized or controlled immune modulation, as systemic overactivation can lead to life-threatening cytokine release syndrome. Ongoing research continues to explore the role of these receptors in the tumor microenvironment, where they may be leveraged to overcome immune evasion in cancer.

Other names

TLR1TLR2TLR3TLR4TLR5CD281CD282CD283CD284CD285Pattern recognition receptorsPRRs

TLR1-5 function by recognizing specific pathogen-associated molecular patterns (PAMPs). Agonists (e.g., MPL for TLR4 or Rintatolimod for TLR3) mimic these patterns to stimulate the innate immune system and are primarily used as vaccine adjuvants or antiviral agents. Antagonists (e.g., Eritoran for TLR4) work by blocking the binding of ligands like lipopolysaccharides or preventing the recruitment of adapter proteins such as MyD88 and TRIF, thereby inhibiting the downstream NF-κB and IRF signaling pathways that lead to systemic inflammation (StatPearls, PMID: 32310523; UniProt, P12755).